Table 1 The details of included studies
Characteristic | Studies, No. (%) (N = 10) | Postmenopausal HR+ Breast Cancer Patients, No. (%) (N = 971) |
|---|---|---|
Study type | ||
 Randomized clinical trial | 7 (70.0) | 676 (69.6) |
 Retrospective | 2 (20.0) | 239 (24.6) |
 Prospective | 1 (10.0) | 56 (5.8) |
Publication date, median (range), y | 2015 (2012–2018) |  |
Follow-up, median (range), moa | 48.1 (17.3–74) |  |
Mean age, median (range), ya | 60.9 (49–70) |  |
Original nation | ||
 the United States | 3 (30.0) | 460 (47.4) |
 Korea | 1 (10.0) | 25 (2.6) |
 Japan | 3 (30.0) | 141 (14.5) |
 the United Kingdom | 1 (10.0) | 44 (4.5) |
 Russia | 1 (10.0) | 239 (24.6) |
 Iran | 1 (10.0) | 62 (6.4) |
Assessment of type of surgery | ||
 Yes | 4 (40.0) | 378 (38.9) |
 No | 6 (60.0) | 593 (61.1) |
Nodes management | ||
 Yes | 1 (10.0) | 221 (22.8) |
 No | 9 (90.0) | 750 (77.2) |
Toxicity | ||
 NET vs NCT | 0 (0.0) | 0 (0.0) |
 NECT vs NET | 2 (20.0) | 113 (11.6) |
 NECT vs NCT | 1 (10.0) | 62 (6.4) |
 Not assessed | 7 (70.0) | 796 (82.0) |
Assessment criteria of tumour response | ||
 RECIST v1.1 | 5 (50.0) | 244 (25.1) |
 WHO | 1 (10.0) | 239 (24.6) |
 Not assessed | 4 (40.0) | 488 (50.3) |
Mainly baseline clinical stage | ||
 T1/2 | 3 (30.0) | 183 (18.8) |
 T3/4 | 3 (30.0) | 441 (45.4) |
 Not assessed | 4 (40.0) | 347 (35.7) |
Length of neoadjuvant treatment | ||
 9–18 ws | 4 (40.0) | 547 (56.3) |
 18–23 ws | 1 (10.0) | 44 (4.5) |
 24 ws | 3 (30.0) | 141 (14.5) |
 Not assessed | 2 (20.0) | 239 (24.6) |
HER2 status | ||
 Negative | 4 (40.0) | 352 (36.3) |
 Negative/Positive | 5 (50.0) | 351/29 (36.1/3.0)b |
 Not assessed | 1 (10.0) | 239 (24.6) |
Research contents | ||
 NET vs NCT | 6 (60.0) | 768 (79.1) |
 NECT vs monotherapy | 4 (40.0) | 203 (20.9) |